Eupraxia Pharmaceuticals Inc.
- | Biotech or pharma, therapeutic R&D
Eupraxia develops new applications for existing products using its highly differentiated delivery technology. Its lead products are EP-104GI which is in Phase 2a/b for Eosinophilic Esophagitis (EOE) and EP-104IAR, Phase 3 ready in Osteoarthritis.
Address
VictoriaBC
Canada
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}